PACE GARY W 4

What Happened
Director Gary W. Pace made a purchase on July 14, 2026: he acquired 687,285 common shares of Cardiff Oncology (CRDF) at $1.46 per share for a total cash outlay of $1,000,000. The filing also shows an acquisition of 687,285 derivative securities (common warrants) at $0 consideration that are tied to the same share amount.

Key Details

• Transaction date: 2026-07-14; Form 4 filed: 2026-07-16 (timely, within standard 2 business days).
• Cash purchase: 687,285 shares @ $1.46 = $1,000,000.
• Derivative acquisition: 687,285 warrants (acquired at $0.00 consideration).
• Footnotes: F1 — warrants become exercisable on the later of (i) six months after issuance or (ii) the date the company increases authorized shares and stockholder approval is obtained; F2 — exercise term is 5.5 years after that Initial Exercise Date.
• Shares owned after the transaction are not specified in the provided excerpt.

Context
Purchases by insiders can be viewed as more informative than sales since they represent a cash commitment; this filing shows both an outright share purchase and receipt of time-locked warrants. The warrants cannot be exercised immediately — they have a delayed exercisability condition and a multi-year exercise window once exercisable. This summary is factual only and does not infer the insider’s motives.